Digital health company AEYE Health, in collaboration with handheld retinal imaging devices provider Optomed, will launch an autonomous diabetic retinopathy screening tool, Aurora AEYE.
The solution is said to be the first portable, AI-powered diabetic retinopathy screening tool designed to deliver immediate diagnostic results.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Approved by the US Food and Drug Administration (FDA), the Aurora AEYE screening tool requires only a single image per eye to provide instant results on the camera screen.
The portable internet-connected design of the tool facilitates screenings in various settings including clinics, bedside and in-home environments.
AEYE Health CEO Zack Dvey-Aharon said: “The launch of Aurora AEYE signifies a major leap in combatting diabetic retinopathy. By introducing FDA-grade AI in a portable camera, we are democratising early detection, making it more accessible and affordable for millions worldwide, eliminating the barriers to traditional healthcare.
“We are delighted to collaborate with Optomed and unveil this groundbreaking technology at the heart of diabetes care, the American Diabetes Association 84th Scientific Session.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAEYE Health said the instant diagnostic reports generated by Aurora AEYE not only benefit patients by providing immediate feedback but also streamline the process for healthcare providers, aiding in insurance reporting and care gap closure.
A dedicated AI CPT code 92229 for autonomous screening simplifies the reimbursement process, thereby improving the accessibility of this essential health service.
Optomed CEO Juho Himberg said: “Aurora AEYE combines our state-of-the-art portable retinal cameras with AEYE’s autonomous AI diagnostics, providing a powerful tool for healthcare providers.
“This innovation enhances patient care and addresses the critical need for more accessible diabetic retinopathy screenings, particularly in remote and home care.”
In April 2024, AEYE Health obtained FDA approval for an autonomous AI, which can diagnose referable diabetic retinopathy from retinal images obtained by a handheld camera.
